Immatics N.V. Presents Updated Clinical Data for IMA203
Ticker: IMTX · Form: 6-K · Filed: Nov 8, 2024 · CIK: 1809196
Sentiment: neutral
Topics: clinical-data, biotech, drug-development
TL;DR
Immatics dropped new data on IMA203, looks promising for cancer treatment.
AI Summary
On November 8, 2024, Immatics N.V. reported updated Phase 1b clinical data for ACTengine® IMA203, showing positive results with a data cutoff of August 23, 2024. The company also presented Phase 1 clinical data for ACTengine® IMA203CD8 and preclinical data for next-generation T cell candidates and combination strategies.
Why It Matters
The presented clinical data could support the advancement of Immatics' cancer therapies, potentially impacting future treatment options for patients.
Risk Assessment
Risk Level: medium — Clinical trial data updates carry inherent risks related to efficacy, safety, and future regulatory approvals.
Key Players & Entities
- Immatics N.V. (company) — Registrant
- ACTengine® IMA203 (drug_candidate) — Clinical trial subject
- ACTengine® IMA203CD8 (drug_candidate) — Clinical trial subject
- August 23, 2024 (date) — Data cutoff date
- November 8, 2024 (date) — Filing date
FAQ
What was the data cutoff date for the updated Phase 1b clinical data on ACTengine® IMA203?
The data cutoff date was August 23, 2024.
What types of data did Immatics N.V. present in their Form 6-K filing on November 8, 2024?
Immatics N.V. presented updated Phase 1b clinical data on ACTengine® IMA203, Phase 1 clinical data on ACTengine® IMA203CD8, and preclinical data on other next-generation T cell candidates and combination strategies.
What is the filing date of this Form 6-K report?
The filing date is November 8, 2024.
What is the primary business of Immatics N.V. according to the filing?
The filing indicates Immatics N.V. is in the business of Biological Products (No Diagnostic Substances).
Which specific clinical trial is mentioned for the updated Phase 1b data?
The updated Phase 1b clinical data is for ACTengine® IMA203.
Filing Stats: 1,969 words · 8 min read · ~7 pages · Grade level 14.2 · Accepted 2024-11-08 17:00:39
Filing Documents
- dp220482_6k.htm (6-K) — 34KB
- dp220482_ex9901.htm (EX-99.1) — 40KB
- dp220482_ex9902.htm (EX-99.2) — 134KB
- image_001.jpg (GRAPHIC) — 1KB
- image_002.jpg (GRAPHIC) — 52KB
- image_003.jpg (GRAPHIC) — 32KB
- image_007.jpg (GRAPHIC) — 4KB
- image_006.jpg (GRAPHIC) — 4KB
- image_005.jpg (GRAPHIC) — 44KB
- ex9902_001.jpg (GRAPHIC) — 258KB
- ex9902_002.jpg (GRAPHIC) — 695KB
- ex9902_003.jpg (GRAPHIC) — 204KB
- ex9902_004.jpg (GRAPHIC) — 233KB
- ex9902_005.jpg (GRAPHIC) — 266KB
- ex9902_006.jpg (GRAPHIC) — 247KB
- ex9902_007.jpg (GRAPHIC) — 353KB
- ex9902_008.jpg (GRAPHIC) — 208KB
- ex9902_009.jpg (GRAPHIC) — 253KB
- ex9902_010.jpg (GRAPHIC) — 361KB
- ex9902_011.jpg (GRAPHIC) — 144KB
- ex9902_012.jpg (GRAPHIC) — 322KB
- ex9902_013.jpg (GRAPHIC) — 291KB
- ex9902_014.jpg (GRAPHIC) — 362KB
- ex9902_015.jpg (GRAPHIC) — 298KB
- ex9902_016.jpg (GRAPHIC) — 421KB
- ex9902_017.jpg (GRAPHIC) — 327KB
- ex9902_018.jpg (GRAPHIC) — 317KB
- ex9902_019.jpg (GRAPHIC) — 322KB
- ex9902_020.jpg (GRAPHIC) — 445KB
- ex9902_021.jpg (GRAPHIC) — 279KB
- ex9902_022.jpg (GRAPHIC) — 244KB
- ex9902_023.jpg (GRAPHIC) — 329KB
- ex9902_024.jpg (GRAPHIC) — 364KB
- ex9902_025.jpg (GRAPHIC) — 312KB
- ex9902_026.jpg (GRAPHIC) — 292KB
- ex9902_027.jpg (GRAPHIC) — 280KB
- ex9902_028.jpg (GRAPHIC) — 356KB
- ex9902_029.jpg (GRAPHIC) — 317KB
- ex9902_030.jpg (GRAPHIC) — 269KB
- ex9902_031.jpg (GRAPHIC) — 295KB
- ex9902_032.jpg (GRAPHIC) — 505KB
- ex9902_033.jpg (GRAPHIC) — 349KB
- ex9902_034.jpg (GRAPHIC) — 326KB
- ex9902_035.jpg (GRAPHIC) — 277KB
- ex9902_036.jpg (GRAPHIC) — 248KB
- ex9902_037.jpg (GRAPHIC) — 374KB
- ex9902_038.jpg (GRAPHIC) — 437KB
- ex9902_039.jpg (GRAPHIC) — 264KB
- ex9902_040.jpg (GRAPHIC) — 143KB
- ex9902_041.jpg (GRAPHIC) — 236KB
- ex9902_042.jpg (GRAPHIC) — 345KB
- ex9902_043.jpg (GRAPHIC) — 266KB
- ex9902_044.jpg (GRAPHIC) — 237KB
- ex9902_045.jpg (GRAPHIC) — 210KB
- ex9902_046.jpg (GRAPHIC) — 267KB
- ex9902_047.jpg (GRAPHIC) — 242KB
- ex9902_048.jpg (GRAPHIC) — 152KB
- ex9902_049.jpg (GRAPHIC) — 399KB
- ex9902_050.jpg (GRAPHIC) — 269KB
- ex9902_051.jpg (GRAPHIC) — 351KB
- ex9902_052.jpg (GRAPHIC) — 309KB
- ex9902_053.jpg (GRAPHIC) — 431KB
- ex9902_054.jpg (GRAPHIC) — 271KB
- ex9902_055.jpg (GRAPHIC) — 212KB
- ex9902_056.jpg (GRAPHIC) — 354KB
- ex9902_057.jpg (GRAPHIC) — 327KB
- ex9902_058.jpg (GRAPHIC) — 392KB
- ex9902_059.jpg (GRAPHIC) — 149KB
- ex9902_060.jpg (GRAPHIC) — 309KB
- ex9902_061.jpg (GRAPHIC) — 209KB
- ex9902_062.jpg (GRAPHIC) — 169KB
- ex9902_063.jpg (GRAPHIC) — 276KB
- ex9902_064.jpg (GRAPHIC) — 223KB
- ex9902_065.jpg (GRAPHIC) — 155KB
- ex9902_066.jpg (GRAPHIC) — 230KB
- ex9902_067.jpg (GRAPHIC) — 340KB
- ex9902_068.jpg (GRAPHIC) — 371KB
- ex9902_069.jpg (GRAPHIC) — 212KB
- ex9902_070.jpg (GRAPHIC) — 240KB
- ex9902_071.jpg (GRAPHIC) — 269KB
- ex9902_072.jpg (GRAPHIC) — 204KB
- ex9902_073.jpg (GRAPHIC) — 241KB
- ex9902_074.jpg (GRAPHIC) — 166KB
- ex9902_075.jpg (GRAPHIC) — 415KB
- ex9902_076.jpg (GRAPHIC) — 311KB
- ex9902_077.jpg (GRAPHIC) — 223KB
- ex9902_078.jpg (GRAPHIC) — 307KB
- ex9902_079.jpg (GRAPHIC) — 248KB
- ex9902_080.jpg (GRAPHIC) — 149KB
- ex9902_081.jpg (GRAPHIC) — 338KB
- ex9902_082.jpg (GRAPHIC) — 173KB
- ex9902_083.jpg (GRAPHIC) — 263KB
- 0000950103-24-016143.txt ( ) — 33524KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: November 8, 2024 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer